MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of $24 million over three years, including CimetrA.
‘We are excited to start the trials in collaboration with University of South Florida at the earliest opportunity this year, particularly with Covid-19 spikes and new variants emerging every few months. We are looking forward to working with our US distribution partners, AMC, to bring CimetrA to the US market, where we believe there is a real need, and expect the treatment to be well received,’ says Chief Executive Officer & Managing Director Roby Zomer.
Current stock price: 0.98 pence, up 6.0% on Friday
12-month change: down 56%
Copyright 2022 Alliance News Limited. All Rights Reserved.
